Ecolab Inc. vs TransMedics Group Inc — how do they compare? Ecolab Inc. trades at $281.83 (market cap $78.97B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Ecolab Inc. is far larger — about 28.8× TransMedics Group Inc's market cap, and Ecolab Inc. pays a 1.04% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and TransMedics Group Inc for 24 Days on average.
| ECL | TMDX | |
|---|---|---|
Market Cap | $78.97B | $2.74B |
Volume | 974,947 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $150.42 |
52-Week Low | $245.73 | $61.99 |
Typical Hold Time | 90 Days | 24 Days |
Enterprise Value | $87.75B | $3.13B |
Dividend Yield | 1.04% | — |
Signals from Pluang's Aura AI — not financial advice
ECL trades at $281.83, up 1.34% today, with strong analyst support (78% buy ratings) and a $326.38 consensus price target. The stock shows bullish technical momentum above key support at $279, while fundamentals reveal steady revenue growth to $16.08B in 2025 and robust profitability with 12.57% net margins. Recent Q2 earnings beat expectations, and the company maintains dividend aristocrat status with consistent payout increases.
Outlook remains positive given ECL's essential service contracts, digital segment growth, and high institutional ownership. Key risks include rising debt from the $4.75B CoolIT acquisition and cost inflation pressures. The stock offers a compelling growth-and-income profile for investors seeking exposure to defensive industrial services with recurring revenue streams.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →